The OJC Episode 37: ASCO 2021 Lung Cancer Roundtable

Pinterest LinkedIn Tumblr +

The Oncology Journal Club Podcast Episode 37: Listen here

In today’s special ASCO 2021 episode Craig Underhill talks to Gilberto Lopes and Mel Moore about all things lung cancer. It’s a thorough and entertaining discussion covering practice changing developments and controversial trials.

We hope you enjoy listening… drop us a line on Twitter with any comments.

This Week’s Papers:

  1. Reck, M. et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. J Clin Oncol 39, 2021 (suppl 15; abstr 9000). DOI: 10.1200/JCO.2021.39.15_suppl.9000. Access online here
  2. Paz-Ares, L.G., et al. Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. J Clin Oncol 39, 2021 (suppl 15; abstr 9016). DOI: 10.1200/JCO.2021.39.15_suppl.9016. Access online here.
  3. Mazieres, J, et al. Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial. J Clin Oncol 39, 2021 (suppl 15; abstr 9015). DOI: 10.1200/JCO.2021.39.15_suppl.9015. Access online here
  4. Spigel, DR., et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. J Clin Oncol 39, 2021 (suppl 15; abstr 8511). DOI: 10.1200/JCO.2021.39.15_suppl.8511. Access online here.
  5. Wakelee, HA., et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol 39, 2021 (suppl 15; abstr 8500). DOI: 10.1200/JCO.2021.39.15_suppl.8500. Access online here
  6. Spira, IA., et al. Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC). J Clin Oncol 39, 2021 (suppl 15; abstr 9057). DOI: 10.1200/JCO.2021.39.15_suppl.9057. Access online here

This Week’s Team:

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill 

Professor Gilberto Lopes

Gilberto Lopes, a medical oncologist, is professor of clinical medicine, medical director for international programs and associate director for Global Oncology at the Sylvester Comprehensive Cancer Center at the University of Miami; he also serves as Editor-in-Chief for the American Society of Clinical Oncology’s JCO Global Oncology. He previously worked at the Johns Hopkins University and was chief medical and scientific officer for the Oncoclinicas Group, the largest oncology provider in Latin America with 35 clinics and more than 300 oncologists in nine states in Brazil. His overarching mission is to improve cancer care and control around the world. As a lead investigator in the study Keynote 42, Gilberto presented the results at ASCO’s plenary session in 2018, leading to FDA extension of approval for pembrolizumab in advanced lung cancer.

Dr. Lopes has published more than 200 papers, delivered lectures around the world and he has been principal, co-Principal Investigator or steering committee member in more than 100 studies and clinical trials.

Dr. Lopes is or has been a committee member for the International Association for the Study of Lung Cancer (IASLC), the European Society of Medical Oncology and the American Society of Clinical Oncology (ASCO), as well as an executive board member for the Latin American Cooperative Oncology Group (LACOG).

Find Gilberto on Twitter here: @GlopesMd

Dr Melissa Moore 

Melissa is a medical oncologist at St Vincent’s Hospital, Melbourne, with sub-specialty interests in cancers of the lung, breast and upper gastrointestinal tract. Her research interests include body composition in cancer patients and the role of exercise.

Dr Moore undertook oncology training in Sydney followed by a lab-based PhD investigating the molecular mechanisms of cancer cachexia. She is the local principal investigator of a number of clinical trials for patients with lung cancer. She is passionate about increasing clinical trial participation.

Find Mel on Twitter here: @DrMelMoore

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Craig Underhill, Gilberto Lopes, Mel Moore and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus #OJC


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.